| __timestamp | Dr. Reddy's Laboratories Limited | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 56369000000 | 25434000 |
| Thursday, January 1, 2015 | 62786000000 | 23783000 |
| Friday, January 1, 2016 | 62427000000 | 29763000 |
| Sunday, January 1, 2017 | 62453000000 | 12065000 |
| Monday, January 1, 2018 | 65724000000 | 5508000 |
| Tuesday, January 1, 2019 | 70421000000 | 75173000 |
| Wednesday, January 1, 2020 | 80591000000 | 81497000 |
| Friday, January 1, 2021 | 86645000000 | 85731000 |
| Saturday, January 1, 2022 | 100551000000 | 63572000 |
| Sunday, January 1, 2023 | 42907000000 | 54922000 |
| Monday, January 1, 2024 | 115557000000 | 41070000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Dr. Reddy's Laboratories Limited, a global pharmaceutical giant, and Mesoblast Limited, a leader in regenerative medicine, offer a fascinating comparison. Over the past decade, Dr. Reddy's has consistently maintained a robust cost of revenue, peaking in 2024 with a staggering 115% increase from 2014. In contrast, Mesoblast's cost of revenue, while significantly lower, saw a notable spike in 2020, increasing by over 220% from 2014, reflecting strategic investments in innovation.
This comparison underscores the diverse strategies in the pharmaceutical sector, where scale and innovation drive financial dynamics.
Cost of Revenue: Key Insights for AbbVie Inc. and Mesoblast Limited
Comparing Cost of Revenue Efficiency: Pfizer Inc. vs Dr. Reddy's Laboratories Limited
Cost Insights: Breaking Down Amgen Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Mesoblast Limited's Expenses
Cost of Revenue: Key Insights for Insmed Incorporated and Mesoblast Limited
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Walgreens Boots Alliance, Inc.
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Xencor, Inc.
Dr. Reddy's Laboratories Limited vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Mesoblast Limited
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Mesoblast Limited
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Mesoblast Limited